Clinical trials: Diabetes, Type 1
Melanoma, Melanoma (Skin)
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with…
- Conditions
- Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- OCTAVA (NCT05732805)
- Testing
- BCD-217, BCD-100
- Where
- 63 sites in Belarus, India and 1 more
- Volunteers
- 270 people
- Sponsor
- Biocad
Type 1 Diabetes Mellitus With Hypoglycemia
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
VC02-101 will evaluate an experimental cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes and Hypoglycemia Unawareness.
- Trial name
- NCT03163511
- Testing
- VC-02 Combination Product
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 49 people
- Sponsor
- ViaCyte
Type 2 Diabetes Mellitus
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01441232
- Testing
- LX4211, Januvia®
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 1
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose…
- Trial name
- TTEDD (NCT00451321)
- Testing
- Otelixizumab
- Where
- 17 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes, Type 2 Diabetes
Remote Monitoring in Diabetes Disease Management
The primary objective of this study is to determine whether remote monitoring in diabetes management is more effective at helping patients manage their disease than a standard disease management program.
- Trial name
- NCT00675311
- Testing
- DM-Standard, Disease Management Plus
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- LifeScan
Type 1 Diabetes Mellitus
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
This is a 2 centres, randomised, double blind, three-treatment, three-period cross-over trial in subjects with type 1 diabetes mellitus.
- Trial name
- NCT02739906
- Testing
- BioChaperone Human Insulin (HinsBet®), Insulin Lispro (Humalog®), Regular human insulin (Huminsulin® Normal)
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 1 (NCT02268214)
- Testing
- Dapagliflozin
- Where
- 131 sites in United States, Australia and 15 more
- Volunteers
- 833 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes
This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00700765
- Testing
- insulin detemir
- Where
- Indonesia
- Volunteers
- 1,531 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Mellitus, Type 2
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of Pf-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- NCT01757756
- Testing
- Pf-05175157, midazolam
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
- Trial name
- STRIVE 2 (NCT07579702)
- Testing
- Omnipod 5 System, Omnipod 6 System
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated haemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 diabetes mellitus (T1DM) also using insulin glargine.
- Trial name
- SORELLA1 (NCT02273180)
- Testing
- SAR342434, Humalog, Insulin glargine HOE901
- Where
- 89 sites in United States, France and 6 more
- Volunteers
- 507 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes
This is a Phase 1, exploratory, single dose, randomized, double-blind, two-way cross over, pilot, glucose clamp study to assess pharmacokinetic and pharmacodynamic effects of Gan \& Lee's insulin glargine injection in comparison…
- Trial name
- NCT02506647
- Testing
- Gan & Lee insulin glargine followed by Lantus, Lantus followed by Gan & Lee insulin glargine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 1
Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes
Many people with diabetes have a desire to share blood glucose data with other members of their team. Using a unique wireless glucose meter device, real-time wireless alerts may be automatically sent to a specific team of…
- Trial name
- NCT00322478
- Testing
- Automated informatics driven education and social networking, Blood Glucose Notifications to Remote Caregivers, Frequency of Pattern Management
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Diabetech
Type 1 Diabetes, Type 2 Diabetes
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
- Trial name
- NCT01798914
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- 14 sites in United States
- Sponsor
- Mannkind Corporation
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
This trial is conducted in Europe. The primary aim of this clinical trial is to locate and compare simulated insulin injections (injections of sterile atmospheric air) in normal weight and obese patients with diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00871416
- Testing
- NovoFine® needle 6 mm, NovoFine® needle 12 mm
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 1 Diabetes Mellitus
Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the 24-hour glycemic profile in continuous glucose monitoring (CGM) between a new formulation of insulin glargine and Lantus at steady state Secondary Objectives: To compare the change of Fasting…
- Trial name
- NCT01676233
- Testing
- insulin glargine (HOE901), insulin glargine- new formulation (HOE901)
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1…
- Trial name
- onset®7 (NCT02670915)
- Testing
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Where
- 155 sites in United States, Bulgaria and 16 more
- Volunteers
- 834 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.